Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease

V2, Crosslink

🧫

Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-biomarke

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease ## Background and Rationale Alzheimer's disease (AD) represents a complex neurodegenerative disorder with heterogeneous pathophysiology, necessitating personalized therapeutic approaches. Current treatment strategies employ a one-size-fits-all paradigm that fails to account for individual patient variations in disease progression, biomarker profiles, and therapeutic responsiveness. This biomarker-guided sequential therapy sel

METHODOLOGY NOTES

Phase 1 (Months 1-3): Recruit 400 AD patients (mild-moderate stages) across 8 clinical sites. Obtain comprehensive baseline biomarker profiles including CSF amyloid-beta42, phosphorylated tau, neurofilament light chain via lumbar puncture, plasma p-tau181/217 via Simoa assays, and 18F-flortaucipir PET imaging. Conduct neuropsychological assessments using ADAS-Cog13, CDR-SB, and MMSE. Phase 2 (Months 4-6): Randomize participants 1:1 to biomarker-guided therapy selection versus standard care. Apply machine learning algorithm incorporating biomarker data, APOE genotype, and cognitive profiles to assign optimal therapy: amyloid-targeting (aducanumab/lecanemab), tau-directed (semorinemab), cholinesterase inhibitors (donepezil/rivastigmine), or combination protocols. Control group receives standard cholinesterase inhibitor therapy. Phase 3 (Months 7-18): Implement assigned therapies with standardized dosing protocols. Conduct biomarker reassessments every 3 months using blood-based assays an

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.901137Z'}
summary	# Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease ## Background and Rationale Alzheimer's disease (AD) represents a complex neurodegenerative disorder with heterogeneous pathophys
entities	{'genes': ['APOE/BDNF/PPARGC1A'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Superior cognitive preservation (CDR-SB score change) at 18 months in biomarker-guided sequential therapy group compared to standard-of-care control, with target effect size of 30% reduction in cognit
methodology_notes	Phase 1 (Months 1-3): Recruit 400 AD patients (mild-moderate stages) across 8 clinical sites. Obtain comprehensive baseline biomarker profiles including CSF amyloid-beta42, phosphorylated tau, neurofi
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.901142', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

629

Outgoing

507

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease

derives from (16)

supports (8)

💬 Discussion